Optimal Degree of Balloon-Expandable Transcatheter Valve Oversizing in Patients With Borderline Aortic Annulus Measurements: Insights From a Multicenter Real-World Experience.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
03 2023
Historique:
entrez: 21 3 2023
pubmed: 22 3 2023
medline: 24 3 2023
Statut: ppublish

Résumé

The potential benefit of using larger or smaller transcatheter heart valves (THV) in patients with borderline aortic annulus measurement (BAM) remains uncertain. The objective of this study was to evaluate the clinical outcomes associated with the selection of larger or smaller THV in the context of BAM. This was a multicenter observational study including patients who underwent transcatheter aortic valve replacement with the SAPIEN 3 or SAPIEN 3 Ultra-valve systems (Edwards Lifesciences, Irvine, CA) from April 2014 to June 2021. BAM was defined according to the manufacturer sizing chart and included the following annulus areas: 314 to 346, 400 to 430, 500 to 546 mm From a total of 2467 patients, BAM was identified in 852 patients (34.5%). A larger and smaller THV was selected in 338 (39.7%) and 514 patients (60.3%) patients, respectively. The choice of a larger THV was associated (before and after propensity matching) with a higher risk of new-onset left bundle branch block (HR, 2.25 [95% CI, 1.39-3.65; In patient with BAM, selecting a larger SAPIEN 3/Ultra THV increased the risk of conduction disturbances without any benefit on valve hemodynamics and clinical outcomes.

Sections du résumé

BACKGROUND
The potential benefit of using larger or smaller transcatheter heart valves (THV) in patients with borderline aortic annulus measurement (BAM) remains uncertain. The objective of this study was to evaluate the clinical outcomes associated with the selection of larger or smaller THV in the context of BAM.
METHODS
This was a multicenter observational study including patients who underwent transcatheter aortic valve replacement with the SAPIEN 3 or SAPIEN 3 Ultra-valve systems (Edwards Lifesciences, Irvine, CA) from April 2014 to June 2021. BAM was defined according to the manufacturer sizing chart and included the following annulus areas: 314 to 346, 400 to 430, 500 to 546 mm
RESULTS
From a total of 2467 patients, BAM was identified in 852 patients (34.5%). A larger and smaller THV was selected in 338 (39.7%) and 514 patients (60.3%) patients, respectively. The choice of a larger THV was associated (before and after propensity matching) with a higher risk of new-onset left bundle branch block (HR, 2.25 [95% CI, 1.39-3.65;
CONCLUSIONS
In patient with BAM, selecting a larger SAPIEN 3/Ultra THV increased the risk of conduction disturbances without any benefit on valve hemodynamics and clinical outcomes.

Identifiants

pubmed: 36943930
doi: 10.1161/CIRCINTERVENTIONS.122.012554
doi:

Types de publication

Observational Study Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e012554

Auteurs

Vassili Panagides (V)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (V.P., J.-M.P., J.M., J.R.-C.).

Asim N Cheema (AN)

St. Michael's Hospital, Toronto, Ontario, Canada (A.N.C.).
Southlake Regional Health Centre, Newmarket, Ontario, Canada (A.N.C., E.R.).

Marina Urena (M)

Assistance Publique-Hôpitaux de Paris, Bichat Hospital, France (M.U., D.H.).

Luis Nombela-Franco (L)

Cardiovascular Institute, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria, Madrid, Spain (L.N.-F., G.T.-C.).

Gabriela Veiga-Fernandez (G)

Hospital Marques de Valdecilla, Santander, Spain (G.V.-F., J.M.d.l.T.H.).

Victoria Vilalta (V)

Department of Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain (V.V., E.F.-N.).

Ander Regueiro (A)

Clínic Barcelona, Spain (A.R., P.L.C.-G., J.R.-C.).

David Del Val (D)

Department of Cardiology, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, IIS-IP, Spain (D.D.V., F.A.).

Lluis Asmarats (L)

Cardiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (L.A., L.G.-A.).

Maria Del Trigo (M)

Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Madrid, Spain (M.d.T., J.F.O.D.).

Vicenç Serra (V)

Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Barcelona, Spain (V.S., Y.B.).

Antonio Munoz-Garcia (A)

Hospital Regional Universitario Virgen de la Victoria, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Málaga, Spain (A.M.-G.).

Effat Rezaei (E)

Southlake Regional Health Centre, Newmarket, Ontario, Canada (A.N.C., E.R.).

Dominique Himbert (D)

Assistance Publique-Hôpitaux de Paris, Bichat Hospital, France (M.U., D.H.).

Gabriela Tirado-Conte (G)

Cardiovascular Institute, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria, Madrid, Spain (L.N.-F., G.T.-C.).

José M de la Torre Hernandez (JM)

Hospital Marques de Valdecilla, Santander, Spain (G.V.-F., J.M.d.l.T.H.).

Eduard Fernandez-Nofrerias (E)

Department of Cardiology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain (V.V., E.F.-N.).

Pedro L Cepas-Guillén (PL)

Clínic Barcelona, Spain (A.R., P.L.C.-G., J.R.-C.).

Fernando Alfonso (F)

Department of Cardiology, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, IIS-IP, Spain (D.D.V., F.A.).

Lola Gutierrez-Alonso (L)

Cardiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (L.A., L.G.-A.).

Juan Francisco Oteo Domínguez (JF)

Servicio de Cardiología, Hospital Universitario Puerta de Hierro, Madrid, Spain (M.d.T., J.F.O.D.).

Yassin Belanech (Y)

Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Barcelona, Spain (V.S., Y.B.).

Jean-Michel Paradis (JM)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (V.P., J.-M.P., J.M., J.R.-C.).

Jules Mesnier (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (V.P., J.-M.P., J.M., J.R.-C.).

Josep Rodés-Cabau (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (V.P., J.-M.P., J.M., J.R.-C.).
Clínic Barcelona, Spain (A.R., P.L.C.-G., J.R.-C.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH